ERBB2 and breast cancer: Together, these results demonstrate that simultaneous inhibition of tGLI1 and GP130 using KCZ and BZA, respectively, is an effective treatment strategy to suppress CSC phenotypes in HER2-enriched breast cancer and TNBC.